Stockscreener 앱 받기
0.341
5.28%
-0.019
시간 외 거래:
.35
0.009
+2.64%
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - The Manila Times
Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight - Meyka
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
EPS Watch: Does Sangamo Therapeutics Inc have consistent dividend growth2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
Sangamo Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Sangamo seeks accelerated US approval of gene therapy for Fabry - Fabry Disease News
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Sangamo Biosciences (SGMO) and Protalix (PLX) - The Globe and Mail
Sangamo Therapeutics (SGMO) shares stabilize amid recent key pipeline update - MSN
Fabry Disease Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Sangamo (SGMO) Advances FDA Submission for Gene Therapy Approval - GuruFocus
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
One-time Fabry gene therapy from Sangamo moves toward FDA accelerated approval - Stock Titan
Sangamo Therapeutics (SGMO) to Release Earnings on Monday - MarketBeat
SGMO PE Ratio & Valuation, Is SGMO Overvalued - Intellectia AI
Day Trade: Is Sangamo Therapeutics Inc. (GBY) stock among top earnings playsTrade Volume Summary & Technical Pattern Alert System - Naître et grandir
Risk Report: Does Sangamo Therapeutics Inc have consistent dividend growth - baoquankhu1.vn
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
Merger Talk: Does Sangamo Therapeutics Inc have consistent dividend growth2025 Buyback Activity & Technical Pattern Based Buy Signals - baoquankhu1.vn
SGMO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sangamo (SGMO) legal chief surrenders shares for RSU tax withholding - Stock Titan
Sangamo (NASDAQ: SGMO) SVP surrenders shares to cover RSU tax withholding - Stock Titan
EDGAR Filing Documents for 0001628280-24-042308 - SEC.gov
symbol__ Stock Quote Price and Forecast - CNN
SGMO Should I Buy - Intellectia AI
Retail Trends: Is Sangamo Therapeutics Inc a strong growth stock2025 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Sangamo Therapeutics (SGMO) price target increased by 17.31% to 3.89 - MSN
How liquid is Sangamo Therapeutics Inc. stockExit Point & Smart Investment Allocation Tips - mfd.ru
Is Sangamo Therapeutics Inc. stock a hidden gem2025 Trading Recap & Consistent Profit Focused Trading Strategies - mfd.ru
Is Sangamo Therapeutics Inc. benefiting from innovation trendsWeekly Investment Report & Expert Verified Movement Alerts - mfd.ru
FY2030 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics' (SGMO) Buy Rating Reiterated at HC Wainwright - MarketBeat
SGMO: HC Wainwright & Co. Maintains Buy Rating with $10 PT | SGM - GuruFocus
Assessing Sangamo Therapeutics (SGMO) Valuation After New Fabry Data Financing Move And Leadership Changes - simplywall.st
Sangamo starts FDA submission seeking approval of Fabry gene therapy - Fabry Disease News
Sangamo prices $25 million offering of common stock and warrants By Investing.com - Investing.com Nigeria
What Sangamo Therapeutics (SGMO)'s Fabry Gene Therapy Progress And Equity Raise Means For Shareholders - Sahm
Sangamo Biosciences launches dilutive February 2026 financing - TipRanks
Sangamo Therapeutics Signs Multiple Material Agreements - TradingView
Form 424B5 SANGAMO THERAPEUTICS, - StreetInsider
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026 - Nasdaq
Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors? - Yahoo Finance
Sangamo (SGMO) Appoints Interim CFO Amid Leadership Change - GuruFocus
Sangamo Therapeutics (SGMO) Price Target Increased by 17.31% to 3.89 - Nasdaq
Sangamo gene therapy shows positive kidney function results in Fabry disease - Investing.com India
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 - The Manila Times
Sangamo gene therapy shows positive kidney function results in Fabry disease By Investing.com - Investing.com South Africa
One-time Fabry gene therapy lifts kidney function in early trial data - Stock Titan
Sangamo Shares Fall After Pricing $25 Million Public Offering - marketscreener.com
Sangamo Therapeutics (SGMO) Stock Plummets 28% After $25M Offeri - GuruFocus
Sangamo stock plunges after pricing $25 million dilutive offering By Investing.com - Investing.com India
Sangamo Prices $250 Mln Offering; Stock Plunges - Nasdaq
Sangamo stock plunges after pricing $25 million dilutive offering - Investing.com
Sangamo plunges after pricing stock offering; principal financial officer exits - Seeking Alpha
Sangamo Therapeutics reports preliminary cash balance and CFO transition By Investing.com - Investing.com Australia
1.20%
0.06%
자본화:
|
볼륨(24시간):